Biomolecular Analysis for Predicting Response to Regorafenib

The study envisages NGS analysis on tumor tissue from patients treated with regorafenib for recurrent glioblastoma as per standard care, with the aim to identify predictive biomarkers for response.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glioblastoma Astrocytoma Glioblastoma, IDH-wildtype Glioma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fondazione Policlinico Universitario A. Gemelli IRCCS

Rome, 00168, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

recurrent glioblastoma after surgery and chemoradiation with temozolomide;
indication to treatment with regorafenib per standard of care;
written informed consent.

Exclusion criteria

None.

Treatment and study plan

Biomolecular tumor analysis

Diagnostic Test

NGS analysis, other molecular analyses on FFPE tumor tissue

Primary outcomes

Overall survival

Time frame: through study completion, an average of 3 years

Interval between tumor diagnosis and death or end of follow-up

Sponsors and collaborators

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Other

Registry information

Official study title

Tumor Biomolecular Analysis for Defining Predictive Factors for Response to Regorafenib in Recurrent Glioblastoma

Acronym: RegoRec

Important dates

Study start: 2021
Primary completion: 2024
Study completion: 2024
First posted: Mar 8, 2023
Registry last updated: Mar 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed